Summary
Rib-X Pharmaceuticals Inc. has raised $50 million in a third round of venture capital financing, the company said Tuesday. "This financing should take us through to our initial public offering," said Rib-X President and CEO Susan Froshauer, noting the company hopes to go public in the latter half of 2007.
Rib-X, founded in 2001, is developing a new class of antibiotics capable of treating antibiotic-resistant infections. The company has one drug candidate in clinical trials and employs 50 people at 300 George St. downtown.See the full content of this document
Extract
Rib-X Secures $50m in Financing
Froshauer said the new infusion of capital will result in some new hires, but she could not say how many at this poi...
See the full content of this document
Sponsored links
